Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News Analysis
Nature Reviews Drug Discovery 4, 809–810 (1 October 2005) | doi:10.1038/nrd1857
Tigecycline
&
Abstract
Tigecycline (Tygacil;Wyeth) was approved by the US FDA for the treatment of a range of bacterial infections in June 2005. It is the first in a new generation of tetracyclines known as glycylcyclines, which have been developed to overcome the problems of resistance to earlier tetracyclines.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
